Teva Pharmaceutical Industries Ltd Receives Consensus Recommendation of “Buy” from Analysts (NASDAQ:TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) has received an average recommendation of “Buy” from the twenty-five brokerages that are presently covering the stock, Analyst Ratings Network.com reports. Eight equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $58.39.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) traded up 1.25% on Thursday, hitting $53.655. 368,422 shares of the company’s stock traded hands. Teva Pharmaceutical Industries Ltd has a 1-year low of $36.26 and a 1-year high of $55.70. The stock has a 50-day moving average of $53.44 and a 200-day moving average of $50.79. The company has a market cap of $45.805 billion and a price-to-earnings ratio of 17.45. Teva Pharmaceutical Industries Ltd also was the target of unusually large options trading activity on Monday. Stock traders acquired 54,686 call options on the stock. This represents an increase of 996% compared to the typical daily volume of 4,990 call options.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last released its earnings data on Thursday, July 31st. The company reported $1.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.21 by $0.02. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the company posted $1.20 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was up 2.5% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Ltd will post $4.94 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, September 4th. Stockholders of record on Thursday, August 21st will be given a dividend of $0.353 per share. This represents a $1.41 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Tuesday, August 19th.
A number of research firms have recently commented on TEVA. Analysts at Maxim Group initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, August 5th. They set a “buy” rating and a $62.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Monday, August 4th. They now have a $57.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Teva Pharmaceutical Industries Ltd from $55.70 to $58.00 in a research note on Friday, August 1st. They now have a “hold” rating on the stock.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.